137 related articles for article (PubMed ID: 12564784)
1. Benefits of combination vaccines: effective vaccination on a simplified schedule.
Dodd D
Am J Manag Care; 2003 Jan; 9(1 Suppl):S6-12. PubMed ID: 12564784
[TBL] [Abstract][Full Text] [Related]
2. Considerations for implementing a new combination vaccine into managed care.
Mullany L
Am J Manag Care; 2003 Jan; 9(1 Suppl):S23-9. PubMed ID: 12564786
[TBL] [Abstract][Full Text] [Related]
3. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Johns TL; Hutter GE
Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
[TBL] [Abstract][Full Text] [Related]
4. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
5. FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2003 Mar; 52(10):203-4. PubMed ID: 12653460
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
[TBL] [Abstract][Full Text] [Related]
7. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
9. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population.
Happe LE; Lunacsek OE; Kruzikas DT; Marshall GS
Pediatr Infect Dis J; 2009 Feb; 28(2):98-101. PubMed ID: 19148039
[TBL] [Abstract][Full Text] [Related]
10. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(39):1079-80. PubMed ID: 18830213
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age.
Lin TY; Wang YH; Chang LY; Chiu CH; Huang YC; Tang H; Bock HL
Chang Gung Med J; 2003 May; 26(5):315-22. PubMed ID: 12934847
[TBL] [Abstract][Full Text] [Related]
12. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.
Avdicová M; Prikazský V; Hudecková H; Schuerman L; Willems P
Eur J Pediatr; 2002 Nov; 161(11):581-7. PubMed ID: 12424582
[TBL] [Abstract][Full Text] [Related]
14. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
15. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
17. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
[TBL] [Abstract][Full Text] [Related]
18. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
19. Recommended childhood immunization schedule--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Jan; 46(2):35-40. PubMed ID: 9011782
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
